Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Catherine Diefenbach, MD, NYU Langone, New York, NY, gives an update on the extended follow-up of the E4412 trial (NCT01896999), which investigated the combination of ipilimumab, nivolumab and brentuximab vedotin in relapsed/refractory Hodgkin lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.